Zhongnan Hospital

This study tests a combination of two drugs, Utidelone and Toripalimab, in people with recurrent or metastatic cervical cancer that has stopped responding to standard treatments. The goal is to see if this therapy can shrink tumors and control the disease. About 32 participants w…

This study tests whether adding an immunotherapy drug (QL1706) to standard chemoradiation helps shrink advanced rectal cancer before surgery. About 108 adults with stage 2 or 3 rectal cancer will be randomly assigned to receive either chemoradiation plus immunotherapy or chemorad…

This phase II trial tests a chemotherapy regimen called FULIRI combined with a targeted drug (bevacizumab or cetuximab) as a first treatment for colorectal cancer that has spread to the liver. The goal is to shrink the liver tumors enough so they can be surgically removed or trea…

This study is testing a new imaging agent called 68Ga-SFB6-ZN01 that attaches to a protein found on many cancer cells. About 98 adults with confirmed or suspected cancer will get one injection and one PET/CT scan. The goal is to see if the agent is safe and can accurately detect …

This study will test a new imaging agent called 68Ga-B6FA-01, which targets two different markers on cancer cells and their surroundings. The goal is to see if this probe can improve PET/CT scans for diagnosing and staging solid tumors. About 100 adults with newly diagnosed or re…

This study tests a non-invasive device called Temporal Interference Stimulation (TIS) to see if it can improve movement in people with Parkinson's disease. The device uses electrical fields to stimulate deep brain areas without surgery. Twenty-four adults with mild to moderate Pa…